This is a 24-week randomized, double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 and 1 mg) in patients with type…
Primary Outcomes: Improvement in glucose control over a 16 week period. Secondary Outcomes: Cholesterol, additional glycemic endpoints, safety endpoints.